Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

November 14, 2019November 14, 2019

Nerve Root Blocks May Pose Risk of CSF ‘Leaks’ in EDS Patients, Case Study Warns

News

A person with Ehlers-Danlos syndrome (EDS), during the course of a routine nerve root block procedure, developed a ‘leak’ of the fluid that normally surrounds the brain and spinal ... Read more

November 7, 2019November 7, 2019

Penn State Award Targets Doctors of Ehlers-Danlos Patients Without Specialty in This Rare Disease

News

The Penn State Clinical and Translational Science Institute is funding seven new projects through its Bridges to Translation pilot grant program. One project aims to improve understanding of Ehlers-Danlos ... Read more

October 9, 2019October 9, 2019

Connecticut Moves Closer to Approving Medical Marijuana for EDS

News

A panel of physicians has voted in favor of adding Ehlers-Danlos syndrome (EDS) to the list of conditions that are eligible for treatment with medical marijuana in Connecticut. According ... Read more

August 21, 2019August 21, 2019

Case of Spontaneous Renal Artery Dissection in EDS Patient Highlighted in Report

News

A diagnosis of spontaneous renal artery dissection (SRAD) should be considered in Ehlers-Danlos syndrome (EDS) patients who experience sudden abdominal pain, a case report highlights. The report, “Spontaneous Renal ... Read more

July 10, 2019July 10, 2019

Ehlers-Danlos Society and Backpack Health Create Digital Platform to Help Patients Manage Their Medical Records

News

The Ehlers-Danlos Society and Backpack Health have announced a partnership to provide patients with Ehlers-Danlos syndrome (EDS) and other related rare diseases with a digital management platform to better access their ... Read more

June 26, 2019July 3, 2019

FDA Rejects New Drug Application for Edsivo, Says Additional Trial Is Needed

News

Acer Therapeutics has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for Edsivo (celiprolol) for treatment of vascular Ehlers-Danlos ... Read more